<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762226</url>
  </required_header>
  <id_info>
    <org_study_id>72311607</org_study_id>
    <nct_id>NCT03762226</nct_id>
  </id_info>
  <brief_title>Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study</brief_title>
  <official_title>Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the influence and prognostic value of systemic factors (such as
      the cardiovascular and metabolic status) on the treatment response to anti-VEGF therapy in
      macular edema due to diabetes or retinal vein occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes patients with macular edema (ME) due to diabetes or retinal vein
      occlusion in the need of treatment.

      At baseline patients underwent an extensive ophthalmological examination (best-corrected
      visual acuity, OCT, OCT-angiography, fluorescein angiography, fundus photography). Besides
      that, systemic work-up (including 24h blood pressure measurement, electrocardiogram, and
      serological blood testing) is conducted.

      Patients underwent routine ME treatment including at least 4 monthly anti-VEGF injections, as
      first-line therapy. Further injections will be conducted if needed. Re-treatment criteria
      are: persistent intra- and/or subretinal fluid seen on SD-OCT, central subfield thickness &gt;
      300 µm. Ophthalmological examination will be repeated at month 3, 6 and month 12. Systemic
      work-up will be repeated at month 6.

      Primary outcome is the correlation of systemic parameters with functional and anatomical
      response at month 6. Secondary outcome is the correlation of systemic parameters with
      functional and anatomical response at month 12.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Correlation of systemic factors on functional and anatomical outcome at month 6.</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between blood pressure and serological Parameters at baseline and visual acuity/central subfield thickness at month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of systemic factors on functional and anatomical outcome at month 12.</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between blood pressure and serological parameters at baseline and visual acuity/central subfield thickness at month 12.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Patient with Macular edema</arm_group_label>
    <description>Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF</intervention_name>
    <description>Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.</description>
    <arm_group_label>Patient with Macular edema</arm_group_label>
    <other_name>Intravitreal anti-VEGF injection</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and heparine blood sample.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with macular edema due to Diabetes or retinal vein occlusion
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;= 18 years

          2. Diagnosis of diabetes mellitus (type 1 or type 2) and/or retinal vein occlusion

          3. macular edema causing visual loss, with study eye VA of 0.1 - 1.0 logMAR (20/25 -
             20/200 Snellen equivalent)

          4. macular edema defined clinically and by retinal thickness of &gt; 300 µm in the central
             subfield thickness (CST) with intra +/- subretinal fluid seen on spectral domain
             optical coherence tomography

          5. last intravitreal treatment &gt; 3 months ago.

        Exclusion Criteria:

          1. concomitant ocular disease that could cause macular edema (including choroidal
             neovascularization from any cause, uveitis or intraocular surgery less than 6 months
             ago).

          2. any concomitant ocular or neurological condition that could affect Vision except of
             cataract.

          3. pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matus Rehak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Leipzig, Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matus Rehak, MD, PhD</last_name>
    <phone>+493419721650</phone>
    <email>matus.rehak@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catharina Busch, MD</last_name>
    <phone>+493419721650</phone>
    <email>catharina.busch@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Leipzig, department of ophthalmology</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>PD Dr. habil. Matus Rehak</investigator_full_name>
    <investigator_title>Prof. MUDr. Matus Rehak</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

